[BKAWAN] YoY Annualized Quarter Result on 31-Dec-2015 [#1]

Stock
[BKAWAN] BATU KAWAN BHD
Announcement Date
17-Feb-2016
Admission Sponsor
-
Sponsor
-
Financial Year
30-Sep-2016
Quarter
31-Dec-2015 [#1]
Profit Trend
QoQ- 219.71%
YoY- 231.35%
Quarter Report
Latest QR
Upcoming QR
BKAWAN's Result
BKAWAN's Financial Summary
View:
Show?
Annualized Quarter Result
31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 CAGR
Revenue 16,875,996 21,366,584 22,519,680 17,801,036 12,858,188 10,347,348 9,598,616 9.85%
PBT 1,451,320 1,947,040 2,055,212 3,754,644 1,273,096 1,639,312 1,510,412 -0.66%
Tax -287,616 -438,420 -417,140 -353,472 -285,888 -333,168 -343,228 -2.90%
NP 1,163,704 1,508,620 1,638,072 3,401,172 987,208 1,306,144 1,167,184 -0.04%
-
NP to SH 546,668 711,596 790,172 1,550,104 467,816 627,888 555,572 -0.26%
-
Tax Rate 19.82% 22.52% 20.30% 9.41% 22.46% 20.32% 22.72% -
Total Cost 15,712,292 19,857,964 20,881,608 14,399,864 11,870,980 9,041,204 8,431,432 10.92%
-
Net Worth 6,310,947 6,635,955 6,452,988 5,944,124 4,869,338 4,715,364 3,897,656 8.35%
Dividend
31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 CAGR
Div - - - - - - - -
Div Payout % - - - - - - - -
Equity
31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 CAGR
Net Worth 6,310,947 6,635,955 6,452,988 5,944,124 4,869,338 4,715,364 3,897,656 8.35%
NOSH 435,951 435,951 435,951 406,296 408,501 413,628 415,971 0.78%
Ratio Analysis
31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 CAGR
NP Margin 6.90% 7.06% 7.27% 19.11% 7.68% 12.62% 12.16% -
ROE 8.66% 10.72% 12.25% 26.08% 9.61% 13.32% 14.25% -
Per Share
31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 CAGR
RPS 4,222.38 5,309.48 5,559.26 4,381.29 3,147.65 2,501.60 2,307.52 10.58%
EPS 136.76 176.84 195.08 381.52 114.52 151.80 133.56 0.39%
DPS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -
NAPS 15.79 16.49 15.93 14.63 11.92 11.40 9.37 9.08%
Adjusted Per Share Value based on latest NOSH - 406,296
31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 CAGR
RPS 4,295.65 5,438.69 5,732.20 4,531.11 3,272.95 2,633.83 2,443.25 9.85%
EPS 139.15 181.13 201.13 394.57 119.08 159.82 141.42 -0.26%
DPS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -
NAPS 16.064 16.8913 16.4256 15.1303 12.3945 12.0026 9.9212 8.35%
Price Multiplier on Financial Quarter End Date
31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 CAGR
Date 31/12/18 29/12/17 30/12/16 31/12/15 31/12/14 31/12/13 31/12/12 -
Price 16.68 19.60 18.40 17.50 17.34 19.60 19.00 -
P/RPS 0.40 0.37 0.33 0.40 0.55 0.78 0.82 -11.27%
P/EPS 12.20 11.08 9.43 4.59 15.14 12.91 14.23 -2.53%
EY 8.20 9.02 10.60 21.80 6.60 7.74 7.03 2.59%
DY 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -
P/NAPS 1.06 1.19 1.16 1.20 1.45 1.72 2.03 -10.25%
Price Multiplier on Announcement Date
31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 CAGR
Date 18/02/19 12/02/18 14/02/17 17/02/16 16/02/15 19/02/14 20/02/13 -
Price 17.22 19.48 19.80 17.80 18.72 20.00 18.58 -
P/RPS 0.41 0.37 0.36 0.41 0.59 0.80 0.81 -10.72%
P/EPS 12.59 11.02 10.15 4.67 16.35 13.18 13.91 -1.64%
EY 7.94 9.08 9.85 21.43 6.12 7.59 7.19 1.66%
DY 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -
P/NAPS 1.09 1.18 1.24 1.22 1.57 1.75 1.98 -9.46%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment